清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020

中止 医学 类风湿性关节炎 相伴的 内科学 泼尼松龙 队列 胃肠病学
作者
Wenhui Xie,Hong Huang,Guangtao Li,Yanjie Hao,Yanni Gui,Yu Wang,Xuerong Deng,Juan Zhao,Yan Geng,Lanlan Ji,Xiaohui Zhang,Zhibo Song,Zhuoli Zhang
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:80 (8): 997-1003 被引量:15
标识
DOI:10.1136/annrheumdis-2021-220112
摘要

To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis (RA) commencing GC with concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).We used data from longitudinal real-world Treat-to-TARget in RA cohort. Patients with RA who started GC and contaminant csDMARDs therapy were included. The changes in GC dose and disease activity were evaluated. GC discontinuation rate was analysed using Kaplan-Meier analysis. The relapse profile within 6 months after GC discontinuation was also analysed.A total of 207 patients with RA were included. During a median follow-up of 38.6 months, 124 patients discontinued GC. The median prednisolone dose of 10 (5-10) mg/day at initiation was reduced by 50% in the first 6 months and then more slowly, to zero by 48 months eventually. The cumulative probabilities of GC discontinuation were 9.7%, 26.6%, 48.0% and 58.6% at month 6, years 1, 2 and 3, with calculated median time to GC cessation of 27 months. In 110 DMARD-naïve patients, the corresponding cumulative probabilities of GC discontinuation were, respectively, 12.7%, 30.0%, 50.9% and 60.6%, with calculated median time to GC cessation of 24 months. Of the 124 patients who discontinued GC, adding other csDMARDs or concomitant csDMARDs increment was documented in 28.2% of them. Approximately half of 124 patients were in clinical remission at GC discontinuation. Within 6 months after GC withdrawal, 79.1% (91/115) of patients maintained relapse free.In patients with RA commencing GC besides csDMARDs, GC is feasibly discontinued with favourable control of disease activity in real-life setting, mostly without short-term flare. But the withdrawal time is far from reaching the recommended time frame, indicating the gap between real-world practice and current guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拓跋雨梅完成签到 ,获得积分0
4秒前
XQL完成签到 ,获得积分10
15秒前
1分钟前
滕皓轩完成签到 ,获得积分10
1分钟前
WXM完成签到 ,获得积分10
2分钟前
3分钟前
清净126完成签到 ,获得积分10
4分钟前
老宇126完成签到,获得积分10
4分钟前
应夏山完成签到 ,获得积分10
5分钟前
清净163完成签到,获得积分10
5分钟前
觀海聴濤完成签到 ,获得积分10
5分钟前
紫熊完成签到,获得积分10
6分钟前
巫巫巫巫巫完成签到 ,获得积分10
7分钟前
娟儿完成签到 ,获得积分10
8分钟前
Robin95完成签到 ,获得积分10
8分钟前
和谐的夏岚完成签到 ,获得积分10
8分钟前
菲菲完成签到 ,获得积分10
10分钟前
lili发布了新的文献求助10
10分钟前
草帽女孩完成签到 ,获得积分10
10分钟前
imi完成签到 ,获得积分10
11分钟前
lili完成签到,获得积分10
11分钟前
aniu完成签到 ,获得积分10
11分钟前
amar完成签到 ,获得积分10
12分钟前
naczx完成签到,获得积分10
12分钟前
正直的宛秋完成签到 ,获得积分10
15分钟前
稻子完成签到 ,获得积分10
15分钟前
17分钟前
冰释之川完成签到 ,获得积分10
17分钟前
clare完成签到 ,获得积分10
17分钟前
如意完成签到 ,获得积分10
18分钟前
轻松的尔风完成签到 ,获得积分10
19分钟前
我是老大应助Lucifer采纳,获得10
19分钟前
大胖熊完成签到 ,获得积分10
19分钟前
墨mo完成签到 ,获得积分10
19分钟前
onevip完成签到,获得积分10
20分钟前
20分钟前
Lucifer发布了新的文献求助10
20分钟前
Lucifer完成签到,获得积分10
20分钟前
monica完成签到 ,获得积分10
21分钟前
21分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545802
求助须知:如何正确求助?哪些是违规求助? 2175669
关于积分的说明 5600226
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557